Published : 11 Jun 2021

---

A Swedish biotech company has chosen Aagami to support them for Partnering including Investment, Licensing, Co-development, and other forms for their innovative therapies in Rheumatoid Arthritis and Covid-19. 

 

Their lead asset for Rheumatoid arthritis (RA) have shown safety and tolerability by patients with moderate-to-severe RA in the Phase 1 and 2 studies. A phase 2b study is planned for Q4 2021. 

 

If you are interested to know more, A non-confidential deck is available for evaluation.

 

Please Contact:

 

Godwyn Francis

Vice President, Aagami Inc.

 

P:  +1-630-364-1837

E: godwyn@aagami.com

 

 Aagami, Inc.                                               

2020 Calamos Court, Suite 200

Naperville, IL 60563, USA